WO2003013562A1 - Artischockenblätterextrakte - Google Patents
Artischockenblätterextrakte Download PDFInfo
- Publication number
- WO2003013562A1 WO2003013562A1 PCT/EP2002/008838 EP0208838W WO03013562A1 WO 2003013562 A1 WO2003013562 A1 WO 2003013562A1 EP 0208838 W EP0208838 W EP 0208838W WO 03013562 A1 WO03013562 A1 WO 03013562A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- ccs
- extracts
- water
- primary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the invention relates to 'extracts from artichoke leaves (folium Cynarae), processes for their preparation and their use in various application fields.
- Primary extracts are usually produced by exhaustive extraction of the fresh or dried leaves at elevated temperature. When extracting with Water is usually required for one part of extract 3 - 8 parts of drug, or 20 - 40 parts of fresh leaves (water content of the fresh leaves: 80 - 90%). The extract yield depends on the quality of the leaves, the extraction conditions and the extracting agent used.
- CCS levels below 6% for primary aqueous extracts can be considered as prior art. Of these, 55 to 69% are mono-CCS and 31 to 45% di-CCS.
- the flavonoid content of aqueous primary extracts is between 0.1% and 1% depending on the drug quality (Table 1).
- Table 1 Total CCS and flavonoid contents as well as proportions of mono-, di-CCS- in the total CCS content in aqueous artichoke leaf dry extracts from commercial preparations (BRAND DAZ 1997; 137: 60-76) and own results according to standard procedures.
- the object of the present invention is to separate the different, in part divergent, activity profiles of aqueous or alcoholic / aqueous primary extracts from one another in order to ensure targeted therapeutic use without undesirable side effects (e.g. a lipid-lowering effect without antidyspeptic effect or vice versa).
- primary extracts are separated by the method according to the invention into two extract fractions A and B, which have a different spectrum of activity. Extract fraction A has a lipid-lowering and cell-protective (antioxidative) effect and an antidyspeptic effect that is no longer present with the primary extract.
- Extract fraction B is a significantly more effective antidyspeptic than the primary extract, but has almost no lipid / cholesterol-lowering properties. Another object is to provide methods for making these extract fractions.
- a first aspect of the invention relates to an extract of artichoke leaves (Cynarae folium), comprising:
- the extract according to the invention has a proportion of mono-CCS below 30%, for example from 3 to 30%, more preferably from 10 to 30% based on the total CCS content, in a further preferred form the ratio of mono-CCS content to flavonoid content is less than 1.
- This extract according to the invention can be obtained by a process for producing an above extract from artichoke leaves (Cynarae folium), comprising the steps:
- Liquid-liquid extraction of a primary extract from fresh or dried artichoke leaves obtained by extraction with water or by extraction with an organic solvent from the series of alcohols, ketones, esters, ethers, preferably methanol, ethanol or mixtures of these compounds with water, with a organic solvent
- a non-polar, water-immiscible solvent preferably one from the series of alkanes, alkenes, ethers, esters or chlorinated hydrocarbons; Separation and discarding of the organic phase.
- an extract of artichoke leaves comprising:
- the ratio of mono-CCS content to flavonoid content is preferably between 4 and 35, e.g. between 5 and 35.
- Liquid-liquid extraction of a primary extract from fresh or dried artichoke leaves obtained by extraction with water or by extraction with an organic solvent from the series of alcohols, ketones, esters, ethers, preferably methanol, ethanol or mixtures of these compounds with water, with a organic solvents from the series of alcohols, ketones, esters, ethers, preferably methanol, ethanol or mixtures of these compounds with water, with a organic solvents from the series of alcohols, ketones, esters, ethers, preferably methanol, ethanol or mixtures of these compounds with water, with a organic solvents from the series of alcohols, ketones, esters, ethers, preferably methanol, ethanol or mixtures of these compounds with water, with a organic solvents from the series of alcohols, ketones, esters, ethers, preferably methanol, ethanol or mixtures of these compounds with water, with a organic solvents from the series of alcohols, ketones, esters, ethers, preferably methanol
- the organic solvent for extracting the primary extract is a mixture of 2-butanol and ethyl acetate, the following steps can also be carried out before the process: Concentrate the primary extract volume, or add water to the primary extract until the extract contains over 50% water.
- a non-polar, water-immiscible solvent preferably one from the series of alkanes, alkenes, ethers, esters or chlorinated hydrocarbons; Separation and discarding of the organic phase.
- the above extracts can be used in the manufacture of drugs, foods, dietetic foods and cosmetics.
- the first-mentioned extracts have an antioxidative, cell- and organ-protective effect and can be used for the treatment and prophylaxis of hypercholesterolemia and hyperlipidemia, for the treatment and prophylaxis of cardiovascular diseases and atherosclerosis and dementias.
- the extracts according to the second aspect of the present invention have an antiserotonergic, spasmolytic, anticholestatic, choleretic, antiemetic, prokinetic effect and can be used to increase vesicular secretion and fat digestion, to treat dyspepsia and to treat IBS (Irritable Bowl Syndrome) become.
- FIG. 1 shows a typical RP-HPLC chromatogram of an aqueous, primary artichoke leaf dry extract Detailed description of the invention
- the invention is based on the surprising finding that aqueous or aqueous / alcoholic primary extracts according to the invention by extractive liquid-liquid
- extract fractions differ significantly with regard to the absolute and relative content of mono-CCS, di-CCS and flavonoids and because of their pharmacological activity profile.
- extract fraction A The extract components, which can be obtained by evaporating the extracting agent loaded after the extraction, are collectively referred to below as "extract fraction A”.
- extract fraction B The constituents remaining in the water-containing phase are collectively referred to as "extract fraction B”.
- the extract fraction A according to the invention is characterized by the enrichment of lipophilic, or depletion of more hydrophilic compounds of the primary extract. This enrichment or depletion comes from a significantly reduced mono-CCS portion and a greatly reduced mono-
- CCS / flavonoid quotients expressed (see Figure 1 and comparison Table 3 with 7).
- the mono-CCS share of the total CCS of this fraction is below 30%, e.g., regardless of the type of primary extractant. 3 to 30%, preferably 10 to 30% depleted compared to the primary extract.
- Extract fraction A is at least 3%, for example at least for aqueous and for alcoholic / aqueous primary extracts, preferably 7 to 20% for aqueous and alcoholic / aqueous primary extracts.
- the mono-CCS / flavonoid quotient of fraction A is reduced to values less than 1 compared to aqueous and alcoholic / aqueous primary extracts.
- the extract fraction B according to the invention is distinguished by the depletion of lipophilic or the addition of more hydrophilic compounds. This depletion or enrichment is expressed by a significantly increased mono-CCS portion and a greatly increased mono-CCS / flavonoid quotient (see Figure 1 and comparison of Table 3 with 7).
- Total CCS contents of at least 1% are found, usually from 2 to 10% when using aqueous primary extracts and usually 3 to 15% when using alcoholic / aqueous primary extracts.
- the mono CCS share of the total CCS share is at least 70%, e.g. increased at least 75% and mostly over 75% to 85%.
- Extract fraction B is at most 2%, preferably 0.02 to 1.5% for aqueous and alcoholic / aqueous primary extracts.
- the mono-CCS / flavonoid ratio of fraction B is increased to values between 4 and 35 compared to the primary extract regardless of the primary extractant, e.g. between 5 and 35.
- the extractant in the processes according to the invention is a non-aqueous extractant, such as an organic solvent.
- organic solvent examples include alcohols, ketones, esters, ethers, aromatics, etc. Aliphatic alcohols and carboxylic acid esters are particularly suitable. These solvents can be used alone or as a mixture of the above compounds. In a particularly preferred In one embodiment, a mixture of 2-butanol and ethyl acetate is used as the extracting agent.
- the comminuted drug is extracted with water.
- the volume of the primary extract can then be reduced to about half in vacuo and is extracted at room temperature with a mixture of 2-butanol and ethyl acetate.
- the fraction soluble in the organic phase is separated off and evaporated to dryness (fraction A).
- the extract contains the amounts of CCS derivatives and flavonoids described above as well as other, unidentified substances.
- the remaining water-containing fraction is also dried (fraction B) ⁇ .
- the comminuted drug is first extracted with an alcoholic / aqueous extracting agent (primary extract).
- primary or secondary alcohols have the chain length from CI to C4. disturbing
- Plant components (e.g. chlorophylls, waxes) of the alcoholic-aqueous primary extracts are extracted from the concentrated water-containing phase with suitable, water-immiscible, non-polar organic solvents such as e.g. Hexane, petroleum ether or dichloroethane removed by extraction.
- suitable, water-immiscible, non-polar organic solvents such as e.g. Hexane, petroleum ether or dichloroethane removed by extraction.
- the aqueous phase (primary extract) is extracted at room temperature with a mixture of 2-butanol and ethyl acetate.
- the fraction soluble in the solvent mixture is separated off and evaporated to dryness (fraction A).
- the extract contains those described above
- the extract fractions A and B differ significantly in the content and composition of the CCS and the flavonoids both from the corresponding parent primary extracts and generally from prior art primary extracts.
- Extract fraction A is a powerful inhibitor of cholesterol biosynthesis and has a very high antioxidative capacity to suppress the formation of free radicals. It has been found that the pharmacological effects are significantly higher than those of the primary extracts.
- fraction A in contrast to the primary extract or extract fraction B, shows little or no effectiveness in a test model for dyspepsia (see Tables 4-6).
- extract fraction B has in contrast to
- Primary extract has a high activity in the dyspepsia model and shows no significant inhibition of cholesterol biosynthesis.
- the antioxidant properties of fraction B are lower (see Tables 4-6 below).
- the extracts A and B described can be processed and applied in customary solid, semi-solid and liquid pharmaceutical and other dosage forms, such as e.g. in powders, solutions, suspensions, tablets, film-coated tablets, coated tablets, capsules, effervescent tablets,
- Common auxiliary substances can be used for the respective dosage form, e.g. Celluloses, silicas, lactose, synthetic polymers, salts, colorings, flavorings, fats, oils, tensides, water and alcohols.
- 300 g artichoke leaf drug are extracted in a 2-stage maceration at 80-90 ° C (5 hours / 3 hours) with a total of 4.5 l of water. Both eluates, which together contain approx. 124 g dry substance, are combined and combined into one
- CCS and flavonoid levels of primary artichoke leaf extracts depend on the levels of the starting drug and the choice of extracting agent.
- High-quality artichoke leaf drug can contain 1 to 7% CCS and 0.2 to 1.2% flavonoids, depending on the variety, origin, harvest time, growing, drying and storage conditions, with the mono-CCS accounting for 40 to 60% of the total Make CCS salary.
- Table 2 and 3 are results of
- the CCS content of aqueous extracts is a maximum of 11% and that of methanolic aqueous maximum 20%.
- the flavonoid content of aqueous extracts can be up to 2.5% and for alcoholic / aqueous extracts up to 3%.
- Table 3 Share of mono-CCS in total CCS contents and mono-CCS / flavonoid quotient in various drug and associated extract batches (examples of commercial commercial drugs A, B and C and high-quality starting drugs)
- the mono-CCS portion of the total CCS content can vary between 49 and 65% for aqueous and between 44 and 59% for methanolic / aqueous extracts.
- the mono-CCS / flavonoid quotient in the extract is in the range from 2.0 to 3.2 when extracted with water and when extracted with Methanol / water between 2.0 and 2.7. Both parameters reflect the relationships of the starting drug almost exactly (Table 3). It should therefore be noted that both aqueous and aqueous / alcoholic extracts have a roughly identical quality compared to each other and to the starting drug.
- extract fraction B The organically extracted aqueous lower phase is concentrated in vacuo at 40 ° C and dried in vacuo at 60 ° C for 2 h. 93.45 g of dry extract are obtained (extract fraction B).
- Example 6 The aqueous phase of Example 6 is concentrated in vacuo to about a 1/3 of its volume and extracted five times with 500 ml of ethyl acetate / 2-butanol (60/40 V / V) each for 3 to 5 min at room temperature. The organic phases are combined. The solvent is removed in vacuo at 40 ° C. The residue is then dried in vacuo at 60 ° C. for 2 h. 16 g of dry extract are obtained (extract fraction A).
- Example 7 The aqueous phase of Example 7 is concentrated in vacuo to about 1/3 of its volume and extracted five times with 500 ml of ethyl acetate / 2-butanol (60/40 V / V) each for 3 to 5 min at room temperature. The organic phases are combined. The solvent was removed in vacuo at 40 ° C. The residue is then dried in vacuo at 60 ° C. for 2 hours. 11 g of dry extract are obtained (extract fraction A)
- extract fraction B The organically extracted aqueous lower phase is concentrated in vacuo at 40 ° C. and then dried in vacuo at 60 ° C. for 2 hours. 57 g of dry extract are obtained (extract fraction B).
- Table 4 Inhibition of cholesterol biosynthesis in rat hepatocytes at an applied concentration of 0.1 mg / ml and 1.0 mg / ml
- the antioxidative capacity was determined according to GUGELER N., peroxidation reactions in artherogenesis: modulators of LDL oxidation and radical formation of macrophages, thesis 1997, Faculty of Biology at the University of Tübingen, Germany.
- Table 5 Inhibition of horseradish peroxidase and xanthine oxidase at an applied concentration of 0.3 ⁇ g / batch
- Table 7 Mono-, di- and total CCS and flavonoid contents of the primary extracts and the associated extract fractions from Examples 4 to 11
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Hospice & Palliative Care (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA04001115A MXPA04001115A (es) | 2001-08-08 | 2002-08-07 | Extractos de hojas de alcachofa. |
IL16008302A IL160083A0 (en) | 2001-08-08 | 2002-08-07 | Artichoke leaf extracts |
CA002455761A CA2455761A1 (en) | 2001-08-08 | 2002-08-07 | Artichoke leaf extracts |
EP02794577A EP1416950A1 (de) | 2001-08-08 | 2002-08-07 | Artischockenblätterextrakte |
US10/486,145 US20040234674A1 (en) | 2001-08-08 | 2002-08-07 | Artichoke leaf extracts |
HU0600153A HUP0600153A3 (en) | 2001-08-08 | 2002-08-07 | Artichoke leaf extracts |
JP2003518569A JP2004537578A (ja) | 2001-08-08 | 2002-08-07 | アーティチョーク葉抽出物 |
PL368184A PL205013B1 (pl) | 2001-08-08 | 2002-08-07 | Sposób wytwarzania ekstraktów z liści karczocha oraz te ekstrakty |
IL160083A IL160083A (en) | 2001-08-08 | 2004-01-27 | Artichoke leaf extracts and methods of preparing them |
NO20040979A NO20040979L (no) | 2001-08-08 | 2004-03-05 | Artisjokkbladekstrakt |
HR20040225A HRPK20040225B3 (en) | 2001-08-08 | 2004-03-05 | Artichoke leaf extracts |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10138929.9 | 2001-08-08 | ||
DE10138929A DE10138929A1 (de) | 2001-08-08 | 2001-08-08 | Artischockenblätterextrakte |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003013562A1 true WO2003013562A1 (de) | 2003-02-20 |
Family
ID=7694791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/008838 WO2003013562A1 (de) | 2001-08-08 | 2002-08-07 | Artischockenblätterextrakte |
Country Status (13)
Country | Link |
---|---|
US (1) | US20040234674A1 (de) |
EP (1) | EP1416950A1 (de) |
JP (1) | JP2004537578A (de) |
CA (1) | CA2455761A1 (de) |
DE (2) | DE10164893B4 (de) |
HR (1) | HRPK20040225B3 (de) |
HU (1) | HUP0600153A3 (de) |
IL (2) | IL160083A0 (de) |
MX (1) | MXPA04001115A (de) |
NO (1) | NO20040979L (de) |
PL (1) | PL205013B1 (de) |
WO (1) | WO2003013562A1 (de) |
YU (1) | YU12404A (de) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007006391A2 (en) * | 2005-07-14 | 2007-01-18 | Indena S.P.A. | Cynara scolymus extracts, the use thereof ans formulations containing them |
CN1301721C (zh) * | 2003-07-23 | 2007-02-28 | 昆明英之源农业科技开发有限公司 | 朝鲜蓟天然抗氧化剂及其提取方法 |
WO2008003638A1 (de) | 2006-07-05 | 2008-01-10 | Coty Prestige Lancaster Group Gmbh | Kosmetische zubereitung mit einem hautpflegekomplex mit anti-alterungswirkung |
FR2936711A1 (fr) * | 2008-10-06 | 2010-04-09 | Holymark | Composition orale, en particulier complement alimentaire comprenant un extrait sec de feuilles d'artichaut et de la levure de riz rouge |
WO2010083968A1 (en) * | 2009-01-20 | 2010-07-29 | Indena S.P.A. | Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome |
ITMI20091358A1 (it) * | 2009-07-29 | 2011-01-30 | Indena Spa | Composizioni a base di estratto lipofilo di zingiber officinale e di estratto di cynara scolymus per la prevenzione e il trattamento del riflusso esofageo e della sindrome del colon irritabile |
ITMI20111670A1 (it) * | 2011-09-16 | 2013-03-17 | Indena Spa | Estratti di cynara scolimus per il trattamento di dislipidemie |
WO2016083992A1 (en) * | 2014-11-25 | 2016-06-02 | Aboca S.P.A Società Agricola | Titled extracts of cynara scolymus and uses thereof |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2883472B1 (fr) * | 2005-03-23 | 2010-09-03 | Rocher Yves Biolog Vegetale | Utilisation d'un acide chlorogenique en tant qu'un actif amincissant |
JP2008148658A (ja) * | 2006-12-20 | 2008-07-03 | Kansai:Kk | アーティチョーク飴及び薬膳用食材 |
ITRM20070109A1 (it) | 2007-02-28 | 2008-09-01 | Massimo Pizzichini | Procedimento per la produzione di estratti nutraceutici raffinati dai residui del carciofo e da altre piante del genere cynara. |
FI123498B (fi) * | 2008-07-01 | 2013-05-31 | Upm Kymmene Oyj | Menetelmä oksapuu-uutteen fraktioimiseksi ja neste-nesteuuton käyttö oksapuu-uutteen puhdistamiseksi |
ITMI20090814A1 (it) * | 2009-05-12 | 2010-11-13 | Biofarmitalia Spa | Estratto delle parti aeree del carciofo e relativo metodo di produzione |
JP2011148708A (ja) * | 2010-01-19 | 2011-08-04 | Noevir Co Ltd | 保湿剤、抗老化剤、抗酸化剤、痩身剤、美白剤、抗炎症剤、免疫賦活剤、皮膚外用剤及び機能性経口組成物 |
JP2011207815A (ja) * | 2010-03-30 | 2011-10-20 | Cci Corp | 抗酸化ストレス剤 |
JP5815566B2 (ja) * | 2011-01-21 | 2015-11-17 | ライオン株式会社 | 脂肪分解促進用組成物 |
JP2013194007A (ja) * | 2012-03-21 | 2013-09-30 | Cci Corp | 抗酸化ストレス剤およびその用途 |
WO2014008901A2 (ar) * | 2012-06-27 | 2014-01-16 | Atawia Ahmed Ahmed Rezk Elsaid | استخدام الخرشوف الصحراوي في القضاء على الألتهاب الكبدى الوبائى (فيروس سى) |
FR3027228B1 (fr) * | 2014-10-20 | 2016-12-09 | Valbiotis | Composition comprenant un melange d'extraits vegetaux et utilisation pour agir sur le metabolisme glucidique et/ou lipidique |
FR3042411B1 (fr) * | 2015-10-20 | 2019-07-12 | Valbiotis | Composition comprenant un melange de molecules particulieres et utilisation pour agir sur le metabolisme glucidique et/ou lipidique |
ES2569132B1 (es) * | 2015-12-31 | 2017-02-15 | Hidroxicinamics, S.L. | Método para la obtención de extractos que comprenden compuestos hidroxicinamicos a partir de residuos vegetales |
CN106496033A (zh) * | 2016-10-17 | 2017-03-15 | 汇美农业科技有限公司 | 一种朝鲜蓟中1,5‑二咖啡酰奎宁酸的提取方法 |
FR3075570B1 (fr) * | 2017-12-22 | 2020-01-03 | Agro Innovation International | Stimulation de la nitrification d'un sol avec des compositions comprenant un extrait de plante |
WO2020209429A1 (ko) * | 2019-04-12 | 2020-10-15 | 주식회사 비엔지삶 | 팔미라팜 및 아티초크의 생리활성성분을 포함하는 인삼 정과 및 이의 제조 방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB802669A (en) * | 1954-05-28 | 1958-10-08 | Farmaceutici Italia | Process for the preparation of 1, 4-dicaffeylquinic acid |
SU644771A1 (ru) * | 1977-06-15 | 1979-01-30 | Харьковский Научно-Исследовательский Химико-Фармацевтический Институт | Способ получени полифенолов |
DE19627376A1 (de) * | 1996-07-06 | 1998-01-08 | Aar Pharma Adler Apotheke | Verwendung von Artischocken-(Cynara)-Extrakten |
EP0958828A1 (de) * | 1998-05-22 | 1999-11-24 | Greither, Peter | Präparat auf der Basis der Artischockenpflanze, insbesondere zur Verwendung als Arzneimittel oder Nahrungsergänzungsmittel |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1195050A (en) * | 1966-09-23 | 1970-06-17 | Ile De Rech Pharma Et Therapeu | Method of Obtaining Depsides and Flavonoids Contained in Plants. |
-
2001
- 2001-08-08 DE DE10164893A patent/DE10164893B4/de not_active Expired - Fee Related
- 2001-08-08 DE DE10138929A patent/DE10138929A1/de not_active Withdrawn
-
2002
- 2002-08-07 JP JP2003518569A patent/JP2004537578A/ja active Pending
- 2002-08-07 WO PCT/EP2002/008838 patent/WO2003013562A1/de active Application Filing
- 2002-08-07 HU HU0600153A patent/HUP0600153A3/hu unknown
- 2002-08-07 YU YU12404A patent/YU12404A/sh unknown
- 2002-08-07 EP EP02794577A patent/EP1416950A1/de not_active Withdrawn
- 2002-08-07 US US10/486,145 patent/US20040234674A1/en not_active Abandoned
- 2002-08-07 IL IL16008302A patent/IL160083A0/xx unknown
- 2002-08-07 CA CA002455761A patent/CA2455761A1/en not_active Abandoned
- 2002-08-07 MX MXPA04001115A patent/MXPA04001115A/es active IP Right Grant
- 2002-08-07 PL PL368184A patent/PL205013B1/pl not_active IP Right Cessation
-
2004
- 2004-01-27 IL IL160083A patent/IL160083A/en not_active IP Right Cessation
- 2004-03-05 NO NO20040979A patent/NO20040979L/no not_active Application Discontinuation
- 2004-03-05 HR HR20040225A patent/HRPK20040225B3/xx not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB802669A (en) * | 1954-05-28 | 1958-10-08 | Farmaceutici Italia | Process for the preparation of 1, 4-dicaffeylquinic acid |
SU644771A1 (ru) * | 1977-06-15 | 1979-01-30 | Харьковский Научно-Исследовательский Химико-Фармацевтический Институт | Способ получени полифенолов |
DE19627376A1 (de) * | 1996-07-06 | 1998-01-08 | Aar Pharma Adler Apotheke | Verwendung von Artischocken-(Cynara)-Extrakten |
EP0958828A1 (de) * | 1998-05-22 | 1999-11-24 | Greither, Peter | Präparat auf der Basis der Artischockenpflanze, insbesondere zur Verwendung als Arzneimittel oder Nahrungsergänzungsmittel |
Non-Patent Citations (12)
Title |
---|
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, GEBHARDT ROLF: "Antioxidative and protective properties of extracts from leaves of the artichoke (Cynara scolymus L.) against hydroperoxide-induced oxidative stress in cultured rat hepatocytes.", XP002222342, Database accession no. PREV199799648613 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1999, SLANINA J ET AL: "1,5-dicaffeoylquinic acid, an antioxidant component of Cynara cardunculus leaves.", XP002222341, Database accession no. PREV200000000742 * |
DATABASE MEDLINE [online] February 2001 (2001-02-01), WALKER A F ET AL: "Artichoke leaf extract reduces symptoms of irritable bowel syndrome in a post-marketing surveillance study.", XP002222340, Database accession no. NLM11180525 * |
DATABASE MEDLINE [online] May 2001 (2001-05-01), GEBHARDT R: "Anticholestatic activity of flavonoids from artichoke (Cynara scolymus L.) and of their metabolites.", XP002222339, Database accession no. NLM12211745 * |
DATABASE WPI Section Ch Week 197943, Derwent World Patents Index; Class B04, AN 1979-78591B, XP002222343 * |
FINTELMANN V: "THERAPEUTIC PROFILE AND MECHANISMS OF ACTION OF ARTICHOKE LEAF EXTRACT: HYPOLIPEMIC, ANTIOXIDANT, HEPATOPROTECTIVE AND CHOLERETIC PROPERTIES", PHYTOMEDICINE, GUSTAV FISCHER VERLAG, STUTTGART, DE, no. SUPPL 1, 1996, pages 50, XP001085492, ISSN: 0944-7113 * |
KRAFT K: "ARTICHOKE LEAF EXTRACT - RECENT FINDINGS REFLECTING EFFECTS ON LIPID METABOLISM, LIVER AND GASTROINTESTINAL TRACTS", PHYTOMEDICINE, GUSTAV FISCHER VERLAG, STUTTGART, DE, vol. 4, no. 4, 1997, pages 369 - 378, XP008000233, ISSN: 0944-7113 * |
MEDICAL SCIENCE MONITOR: INTERNATIONAL MEDICAL JOURNAL OF EXPERIMENTAL AND CLINICAL RESEARCH. POLAND MAY 2001, vol. 7 Suppl 1, May 2001 (2001-05-01), pages 316 - 320, ISSN: 1234-1010 * |
PETROWICZ O ET AL: "EFFECTS OF ARTICHOKE LEAF EXTRACT (ALE) ON LIPOPROTEIN METABOLISM IN VITRO AND IN VIVO", ATHEROSCLEROSIS, AMSTERDAM, NL, no. 129, 28 February 1997 (1997-02-28), pages 147, XP001055124, ISSN: 0021-9150 * |
PHYTOTHERAPY RESEARCH: PTR. ENGLAND FEB 2001, vol. 15, no. 1, February 2001 (2001-02-01), pages 58 - 61, ISSN: 0951-418X * |
SCRIPTA MEDICA (BRNO), vol. 72, no. 1, 1999, pages 9 - 18, ISSN: 0036-9721 * |
TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 144, no. 2, 1997, pages 279 - 286, ISSN: 0041-008X * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1301721C (zh) * | 2003-07-23 | 2007-02-28 | 昆明英之源农业科技开发有限公司 | 朝鲜蓟天然抗氧化剂及其提取方法 |
WO2007006391A3 (en) * | 2005-07-14 | 2007-04-19 | Indena Spa | Cynara scolymus extracts, the use thereof ans formulations containing them |
WO2007006391A2 (en) * | 2005-07-14 | 2007-01-18 | Indena S.P.A. | Cynara scolymus extracts, the use thereof ans formulations containing them |
WO2008003638A1 (de) | 2006-07-05 | 2008-01-10 | Coty Prestige Lancaster Group Gmbh | Kosmetische zubereitung mit einem hautpflegekomplex mit anti-alterungswirkung |
CN101484122B (zh) * | 2006-07-05 | 2011-06-22 | 科蒂·普雷斯蒂奇·兰嘉斯汀集团有限公司 | 包含具有抗老化作用的皮肤护理复合物的美容制品 |
US7968129B2 (en) | 2006-07-05 | 2011-06-28 | Coty Prestige Lancaster Group Gmbh | Cosmetic skin care complex with anti-aging effect |
FR2936711A1 (fr) * | 2008-10-06 | 2010-04-09 | Holymark | Composition orale, en particulier complement alimentaire comprenant un extrait sec de feuilles d'artichaut et de la levure de riz rouge |
AU2010206327B2 (en) * | 2009-01-20 | 2015-06-04 | Indena S.P.A. | Compositions comprising a lipophilic extract of Zingiber officinale and an extract of Cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome |
WO2010083968A1 (en) * | 2009-01-20 | 2010-07-29 | Indena S.P.A. | Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome |
JP2012515716A (ja) * | 2009-01-20 | 2012-07-12 | インデナ エッセ ピ ア | 食道逆流および過敏性腸症候群の予防および治療に有用な、ショウガの親油性抽出物およびアーティチョークの抽出物を含む組成物 |
US10220065B2 (en) | 2009-01-20 | 2019-03-05 | Indena S.P.A. | Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome |
ITMI20091358A1 (it) * | 2009-07-29 | 2011-01-30 | Indena Spa | Composizioni a base di estratto lipofilo di zingiber officinale e di estratto di cynara scolymus per la prevenzione e il trattamento del riflusso esofageo e della sindrome del colon irritabile |
ITMI20111670A1 (it) * | 2011-09-16 | 2013-03-17 | Indena Spa | Estratti di cynara scolimus per il trattamento di dislipidemie |
CN103874498A (zh) * | 2011-09-16 | 2014-06-18 | 因德纳有限公司 | 用于治疗血脂异常症的洋蓟提取物 |
RU2608459C2 (ru) * | 2011-09-16 | 2017-01-18 | Индена С.П.А. | Экстракты CYNARA SCOLYMUS для лечения дислипидемии |
AU2012307404B2 (en) * | 2011-09-16 | 2017-05-25 | Indena S.P.A. | Cynara scolymus extracts for the treatment of dyslipidaemia |
US9687468B2 (en) | 2011-09-16 | 2017-06-27 | Indena S.P.A. | Cynara scolymus extracts for the treatment of dyslipidaemia |
WO2013037857A1 (en) * | 2011-09-16 | 2013-03-21 | Indena S.P.A. | Cynara scolymus extracts for the treatment of dyslipidaemia |
WO2016083992A1 (en) * | 2014-11-25 | 2016-06-02 | Aboca S.P.A Società Agricola | Titled extracts of cynara scolymus and uses thereof |
WO2016083993A1 (en) * | 2014-11-25 | 2016-06-02 | Aboca S.P.A Società Agricola | Titled extracts of cynara scolymus for use in the treatment of mesothelioma |
AU2015352042B2 (en) * | 2014-11-25 | 2018-06-21 | Aboca S.P.A Società Agricola | Titled extracts of Cynara scolymus for use in the treatment of mesothelioma |
AU2015352041B2 (en) * | 2014-11-25 | 2018-08-23 | Aboca S.P.A Societa Agricola | Titled extracts of Cynara scolymus and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1416950A1 (de) | 2004-05-12 |
HUP0600153A2 (en) | 2006-06-28 |
DE10164893B4 (de) | 2008-08-28 |
IL160083A0 (en) | 2004-06-20 |
HRP20040225A2 (en) | 2005-04-30 |
PL205013B1 (pl) | 2010-03-31 |
HUP0600153A3 (en) | 2011-03-28 |
IL160083A (en) | 2010-11-30 |
PL368184A1 (en) | 2005-03-21 |
NO20040979L (no) | 2004-03-05 |
US20040234674A1 (en) | 2004-11-25 |
DE10138929A1 (de) | 2003-02-27 |
YU12404A (sh) | 2006-08-17 |
CA2455761A1 (en) | 2003-02-20 |
HRPK20040225B3 (en) | 2006-07-31 |
MXPA04001115A (es) | 2005-02-17 |
JP2004537578A (ja) | 2004-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10164893B4 (de) | Verfahren zur Herstellung von Artischockenblätterextrakten und so erhaltene Artischockenblätterextrakte | |
DE69531688T2 (de) | Extrakt aus chinesischen kräutern | |
EP1267900B1 (de) | Emulsion enthaltend einen triterpen-haltigen pflanzenextrakt, verfahren zur herstellung der emulsion sowie zur gewinnung des pflanzenextraktes | |
WO2003014287A1 (de) | Hopfenextrakte, verfahren zu ihrer herstellung und verwendung | |
EP2222320B1 (de) | Neuer mariendistelextrakt, verfahren zur herstellung und verwendung | |
DE69819006T2 (de) | Verwendung von ginsenoside rb1 zur stimulierung der elastinsynthese | |
EP2057994A1 (de) | Feigenkakteen-Extraktzubereitung | |
EP2320922B1 (de) | Kombination von extrakten aus verschiedenen pflanzen zur verbesserung der symptome von demenzerkrankungen | |
EP2182966B1 (de) | Verwendung von extrakten oder extraktivstoffen aus piper cubeba l. als wirksame bestandteile in einem medikament zur behandlung von krebserkrankungen | |
EP1663269B1 (de) | Verfahren zur herstellung eines lagerstabilen extraktes aus efeublättern, sowie ein nach diesem verfahren hergestellter extrakt | |
EP2069334B2 (de) | Aspalathin-ähnliches dihydrochalcon, extrakte aus unfermentiertem rotbusch und verfahren zur herstellung | |
DE10308162A1 (de) | Verfahren zur Herstellung von Flavonoid-haltigen Zusammensetzungen und ihre Verwendung | |
EP1399173B1 (de) | Pharmazeutische zubereitung enthaltend wirkstoffe aus den pflanzen centella asiatica, mahonia aquifolium und viola tricolor | |
EP0897302B1 (de) | Harpagosid-angereicherter extrakt aus harpagophytum procumbens und verfahren zu seiner herstellung | |
EP0904092B1 (de) | Gereinigter extrakt von harpagophytum procumbens und/oder harpagophytum zeyheri dence, verfahren zu seiner herstellung und seine verwendung | |
EP0505519B1 (de) | Kawa-kawa-extrakt, verfahren zu seiner herstellung und seine verwendung | |
WO2013007807A1 (de) | Ausgewählte cimicifuga-fraktionen zur behandlung von osteoporose | |
WO2020182822A1 (de) | Safranknollenextrakt zur behandlung von entzündungen | |
DE19746284A1 (de) | Kosmetische und pharmazeutische Mittel auf Basis eines Kamillenextraktes | |
CH685373A5 (de) | Verfahren für die Herstellung von Heilpflanzenextrakten. | |
DE4320889A1 (de) | Neue extrahierte Substanz mit Anti-HIV-Aktivität | |
WO2005058338A1 (de) | Verwendung eines extraktes von aloysia/verbena/lippia triphylla/citriodora zur behandlung chronischer und/oder entzündlicher erkrankungen | |
DE2135492B2 (de) | Gewinnung eines Anacardium occidentale L-Rindenextraktes mit antihypertensiver Wirkung | |
EP1707213A1 (de) | Pflanzliche Zusammensetzung zur Behandlung von erythematösen Hautveränderungen | |
EP2545932A1 (de) | Ausgewählte Cimicifuga-Fraktionen zur Behandlung von Osteoporose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-124/04 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG AE AG AL AM AT AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ OM PH PL PT RO RU SD SE SI SK SL TJ TM TN TR TT TZ UA UG UZ VC YU ZA ZM ZW GH GM KE LS MW MZ SL SZ TZ UG ZM ZW Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 160083 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2455761 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/001115 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003518569 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PK20040225A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002794577 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002794577 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10486145 Country of ref document: US |